Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vivo monitoring of antimalarial sensitivity to pyronaridine-artesunate and artemether-lumefantrine in Niger
PACTR202105706263530Phase 4Completed
- Sponsor
- Université des Sciences, des Techniques et des Technologies de Bamako
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pyronaridine and artemether + lumefantrine in malaria (2 arms), sponsored by Université des Sciences, des Techniques et des Technologies de Bamako. Primary endpoint: Sensitivity of Plasmodium falciparum to pyronaridine-artesunate and artemether-lumefantrine. Started Nov 2019; status: completed.
02
Drugs
pyronaridineartemether + lumefantrine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202105706263530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202105706263530.